Randomized, multicentre, prospective, two-arm, open-label Phase II study to investigate the efficacy and safety of two ZK219477 i.v. infusions (3-hour infusion of 16mg/m2 versus 0.5-hour infusion of 16mg/m2) in patients with recurrent ovarian cancer progressing during, or within 6 months of the end of platinum-based chemotherapy

Registry ID

EUCTR2005-000635-15

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

Schering AG

Start date

2005-07-06

Completion date

2007-06-26

Last update

2026-08-16

Conditions

• Recurrent ovarian cancer

Summary

To investigate the efficacy of ZK 219477 in patients with recurrent ovarian cancer progressing during, or within 6 months of platinum-based chemotherapy (proof of concept)

Locations

• , , UK

View on source registry